Biocon Biologics to Launch Yesafili Aflibercept Biosimilar in U.S. After 2026 Per Regeneron Settlement

Biocon Biologics will commercialize its Yesafili, an interchangeable aflibercept biosimilar, in the United States following a settlement agreement with Regeneron. The launch of Yesafili is anticipated in the second half of 2026, or possibly earlier if certain conditions are met. The agreement resolves ongoing patent disputes, paving the way for Biocon Biologics to enter the U.S. market with its biosimilar version of aflibercept. Yesafili is designed to be interchangeable with Regeneron’s reference product, potentially offering a cost-effective alternative for patients. The specific conditions that could trigger an earlier launch date remain unspecified in the announcement.

Newsflash | Powered by GeneOnline AI
Date: April 15, 2025

Related posts:

FDA Approves Pfizer/BioNTech’s COVID-19 Vaccine for 5- to 11-Year-Olds Generic Drug Demand Soars in Emerging Markets Amid Growing Healthcare Needs Analysis: CDMO Partnerships Offer Pharmaceutical Firms Faster Market Entry and Cost Reduction in Drug Development Guide Explores Drug Pricing, Highlights Patent Expirations’ Impact

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後